Updates on the Version 9 American Joint Committee on Cancer Staging System for Anal Cancer

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 May 12

PMID 38735904

Authors

Lauren M Janczewski

Elliot A Asare

Karyn A Goodman

Affiliations

Soon will be listed here.

Citing Articles

Comparative evaluation of TNM staging systems (eighth vs. ninth edition) for the non-surgical treatment of localized and locally advanced anal squamous cell carcinoma: Prognostic significance of T classification and lymph node status.

Zheng A, Xu H, Tao Y, Chen B, Ding J, Song T PLoS One. 2025; 20(1):e0317598.

PMID: 39820172 PMC: 11737782. DOI: 10.1371/journal.pone.0317598.

Reply: Letter to the Editor of Annals Surgical Oncology Concerning "Updates on the Version 9 American Joint Committee on Cancer Staging System for Anal Cancer." Is the Anal Physical Examination Underestimated?.

Janczewski L, Asare E, Goodman K Ann Surg Oncol. 2024; 32(2):1134-1135.

PMID: 39653941 DOI: 10.1245/s10434-024-16636-4.

Metastasis patterns and prognosis in patients with gastric cancer: a Surveillance, Epidemiology, and End Results-based analysis.

Dong Q, Huang M, Lai X J Gastrointest Oncol. 2024; 15(5):2079-2087.

PMID: 39554562 PMC: 11565122. DOI: 10.21037/jgo-24-738.

Concerning "Updates on the Version 9 American Joint Committee on Cancer Staging System for Anal Cancer": Is the Anal Physical Examination Underestimated?.

Zinicola R, Viani L, Rossini M, Cozzani F Ann Surg Oncol. 2024; 32(2):1132-1133.

PMID: 39550479 DOI: 10.1245/s10434-024-16554-5.

Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.

English K World J Exp Med. 2024; 14(3):98525.

PMID: 39312693 PMC: 11372733. DOI: 10.5493/wjem.v14.i3.98525.

References

Amin M, Greene F, Edge S, Compton C, Gershenwald J, Brookland R . The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67(2):93-99. DOI: 10.3322/caac.21388. View

Leichman L, Nigro N, VAITKEVICIUS V, Considine B, Buroker T, Bradley G . Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med. 1985; 78(2):211-5. DOI: 10.1016/0002-9343(85)90428-0. View

Janczewski L, Browner A, Cotler J, Nelson H, Ballman K, LeBlanc M . Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. Cancer. 2023; 130(9):1702-1710. DOI: 10.1002/cncr.35155. View

Janczewski L, Faski J, Nelson H, Gollub M, Eng C, Brierley J . Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer. CA Cancer J Clin. 2023; 73(5):516-523. DOI: 10.3322/caac.21780. View

Mistrangelo M, Pelosi E, Bello M, Ricardi U, Milanesi E, Cassoni P . Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys. 2012; 84(1):66-72. DOI: 10.1016/j.ijrobp.2011.10.048. View

Pernicka J, Sheedy S, Ernst R, Minsky B, Ganeshan D, Rauch G . MR staging of anal cancer: what the radiologist needs to know. Abdom Radiol (NY). 2019; 44(11):3726-3739. DOI: 10.1007/s00261-019-02020-4. View

Glynne-Jones R, Nilsson P, Aschele C, Goh V, Peiffert D, Cervantes A . Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014; 111(3):330-9. DOI: 10.1016/j.radonc.2014.04.013. View

Mistrangelo M, Pelosi E, Bello M, Castellano I, Cassoni P, Ricardi U . Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys. 2009; 77(1):73-8. DOI: 10.1016/j.ijrobp.2009.04.020. View

Cotter S, Grigsby P, Siegel B, Dehdashti F, Malyapa R, Fleshman J . FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65(3):720-5. DOI: 10.1016/j.ijrobp.2006.01.009. View

10.

Gunderson L, Moughan J, Ajani J, Pedersen J, Winter K, Benson 3rd A . Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013; 87(4):638-45. PMC: 3938865. DOI: 10.1016/j.ijrobp.2013.07.035. View

11.

Gunderson L, Winter K, Ajani J, Pedersen J, Moughan J, Benson 3rd A . Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012; 30(35):4344-51. PMC: 3515768. DOI: 10.1200/JCO.2012.43.8085. View

12.

James R, Glynne-Jones R, Meadows H, Cunningham D, Myint A, Saunders M . Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013; 14(6):516-24. DOI: 10.1016/S1470-2045(13)70086-X. View

13.

Salama J, Mell L, Schomas D, Miller R, Devisetty K, Jani A . Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007; 25(29):4581-6. DOI: 10.1200/JCO.2007.12.0170. View

14.

Palefsky J, Lee J, Jay N, Goldstone S, Darragh T, Dunlevy H . Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med. 2022; 386(24):2273-2282. PMC: 9717677. DOI: 10.1056/NEJMoa2201048. View